Publications by authors named "A Krasner"
Microcystin (MC), a hepatotoxin produced by cyanobacteria, was introduced into the Indian River Lagoon (IRL), Florida, in 2005 through freshwater outflows. Since then, MC has been detected in humans, domestic animals, and wildlife in the lagoon. Potential public health effects associated with MC exposure along the IRL include an increased risk of non-alcoholic liver disease among area residents.
View Article and Find Full Text PDFArticle Synopsis
- The review examines the rising mental health crises among children and youth, revealing that 1 in 5 children face mental health disorders, worsened by the stressors of the COVID-19 pandemic.
- Key issues include increasing substance use, specifically among adolescents, with a notable rise in overdose deaths, and significant disparities affecting students of diverse racial backgrounds.
- Proposed solutions involve improving access to treatments, early identification strategies, school-based interventions, and education for healthcare professionals to manage these escalating complexities.
Objective: This study examined the unique and interactive effects of PA volume and within-person fluctuations in PA volume (i.e., intraindividual variability in PA volume; PA-var) on preschoolers' ( = 141; 47.
View Article and Find Full Text PDFArticle Synopsis
- The study assessed the presence of the liver toxin microcystin and trace element accumulation in North American river otters from the Indian River Lagoon, Florida, due to the lack of routine contaminant screening.
- Out of 43 river otters tested, microcystin was not found in any samples, and trace elements were at background levels, with some variation tied to sex, but no concerning bioaccumulation was noted.
- Histopathological evaluations revealed some liver and kidney anomalies in a small percentage of otters, yet these were not directly associated with microcystin or harmful trace elements, suggesting alternative causes like infectious diseases should be explored.
Context: Paltusotine is a nonpeptide selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly.
Objective: To evaluate the efficacy and safety of paltusotine in the treatment of patients with acromegaly previously controlled with injected somatostatin receptor ligands (SRLs).
Methods: This phase 3, randomized, double-blind, placebo-controlled trial enrolled adults with acromegaly who had IGF-I ≤1.